Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $100.7052W HIGH $212.00
Volume
668.32 K
Value Traded
133.49 M
Short % Float
9.47%
-7.04%Week
-14.19%1 Month
-11.65%3 Month
-10.97%6 Month
+51.06%5 Year
+335.74%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.31 B
EPS (TTM)
-0.42
P/E Ratio
-
Ent. Value
3.37 B
Total Shares
32.22 M
Float Shares
32.27 M
Insiders
2.09%
Institutions
108.82%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
IRTC Catalyst Timeline
Dated clinical, regulatory and corporate events for iRhythm Holdings, Inc.
Past FDA Catalysts and PDUFA Decisions
How IRTC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
iRhythm Holdings, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every IRTC program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Wilson Daniel G.Officer (Chief Financial Officer) | Sell | -773 34,887 held | $121.83 | 09/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IRTC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 2.2 % (10 %) | 259.62 M | 2.18 M | 30.81% ( 514.13 K) |
IRTC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IRTC ranks across every disease it competes in
Competitive Position is a premium feature
See how IRTC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIRTC News
IRTCKuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
Kuehn Law is investigating potential breaches of fiduciary duties by officers and directors of iRhythm Technologies, Inc. The investigation stems from allegations that insiders misrepresented the Zio AT monitor's intended use for high-risk patients, leading to artificially inflated stock prices. Shareholders are encouraged to contact the law firm for participation in the investigation.
Read more →IRTC▲ +7%on this news
Three Months Ended
iRhythm Holdings, Inc. announced its financial results for the first quarter of 2026, showing significant growth with a revenue increase of 25.7% compared to the previous year. The gross margin also improved to 70.9%, a positive sign of operational efficiency. Despite these gains, the company still reported a net loss of $13.9 million. Looking forward, iRhythm has raised its revenue guidance for the year to between $875 million and $885 million, underlining confidence in ongoing demand for its services.
Read more →IRTCiRhythm Holdings Announces Fourth Quarter and Full Year 2025 Financial Results
iRhythm Holdings announced its financial results for Q4 and the full year 2025, showcasing significant revenue growth and the first positive GAAP net income in its history. The company's revenue for Q4 reached $208.9 million, up 27.1% year-over-year, while full-year revenue rose to $747.1 million. Despite these gains, iRhythm reported a net loss of $44.6 million for the year, though this marked an improvement compared to the previous year. Overall, the results indicate a strong demand for iRhythm's Zio services and effective cost management, setting a positive outlook for 2026.
Read more →IRTCThree Months Ended September 30, Nine Months Ended
iRhythm Technologies, Inc. reported its financial results for the third quarter of 2025, highlighting a significant revenue increase of 30.7% year-over-year to $192.9 million. The company's gross margin improved to 71.1%, indicating better operational efficiencies and cost management. Additionally, iRhythm has increased its fiscal year 2025 revenue guidance, reflecting strong demand for its Zio services. However, the company still reported a net loss of $5.2 million, although this marks a substantial improvement compared to the previous year.
Read more →IRTCThree Months Ended June 30, Six Months Ended
iRhythm Technologies, Inc. reported strong financial results for the second quarter of 2025, with revenue of $186.7 million, a 26.1% increase from the same quarter in 2024. The gross margin improved to 71.2%, benefiting from operational efficiencies. The company has partnered with Lucem Health to advance early detection of arrhythmias, while maintaining guidance for total revenue of $720 to $730 million for the fiscal year 2025. However, operating expenses also rose, leading to a net loss of $14.2 million despite the overall positive growth trajectory.
Read more →IRTCiRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results
iRhythm Technologies, Inc. reported its financial results for Q4 and full year 2024, showcasing significant revenue growth and operational improvements. The company's revenue for Q4 2024 increased 24.0% year-over-year, with a notable reduction in net loss. Additionally, iRhythm holds $535.6 million in cash and marketable securities. Despite the positive outlook, the overall net loss for the year remains substantial, prompting scrutiny of future expense management and operational efficiency.
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (in thousands, except per share data) (unaudited) Three Months Ended September 30, Nine Months Ended
iRhythm Technologies, Inc. reported a strong financial performance in the third quarter of 2024, with revenues up 18% year-over-year, amounting to $147.5 million. The company achieved a gross margin of 68.8% due to increased demand for its services and operational efficiencies. However, despite the revenue growth, iRhythm experienced a net loss of $46.2 million, largely driven by a $32.1 million charge from a technology licensing agreement. Additionally, operating expenses markedly increased, raising concerns about cost management even as the company expands its market presence and product offerings.
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (unaudited) (in thousands, except per share data) Three Months Ended June 30, Six Months Ended
iRhythm Technologies, Inc. reported a strong performance in its second quarter of 2024, with a revenue of $148 million, marking a 19.3% increase year-over-year. The company also announced improved gross margins of 69.9% and raised its full-year guidance for revenue and profitability. Notable operational achievements include preparations for launches in four European countries and ongoing advancements in manufacturing processes. However, the company reported an increased net loss and rising operating expenses, which could impact financial sustainability.
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (unaudited) (in thousands, except per share data) Three Months Ended
iRhythm Technologies reported a strong financial performance for Q1 2024, achieving $131.9 million in revenue, an 18.4% increase compared to Q1 2023. The company has also raised its revenue guidance for the full year to a range of $578 million to $588 million due to robust demand for its Zio services. However, the gross margin has decreased to 66.3%, and the net loss has increased to $45.7 million, which poses concerns regarding ongoing operational costs. Upcoming data presentations and collaborations highlight iRhythm's commitment to improving cardiac monitoring and integrating digital health solutions.
Read more →IRTCDealer name and address ] [March __], 2024 To: iRhythm Technologies, Inc. 699 8 th Street, Suite 600 San Francisco, CA 94103 Attention: Legal Department Re: [Base][Additional] Call Option Transaction The purpose of this
iRhythm Technologies, Inc. has entered into a call option transaction with a dealer, confirming terms of the agreement as outlined in a letter agreement. The transaction involves the issuance of Convertible Senior Notes due 2029, and the agreement is governed by ISDA standards. This confirmation includes various details such as trade dates, strike prices, and expiration terms, but does not indicate any immediate changes in company operations or outlook.
Read more →IRTCIRHYTHM PRICES UPSIZED OFFERING OF $575.0 MILLION OF 1.50% CONVERTIBLE SENIOR NOTES DUE 2029 SAN FRANCISCO, MARCH 4, 2024 (GLOBE NEWSWIRE) iRhythm Technologies, Inc. ( iRhythm ) (NASDAQ: IRTC), a leading digital health c
iRhythm Technologies, Inc. has announced the pricing of its upsized offering of $575.0 million of 1.50% Convertible Senior Notes due 2029. The offering size was increased from a previously stated $450.0 million, reflecting strong institutional demand. The company plans to use the net proceeds for various purposes, including debt repayment and corporate growth activities. The sale is expected to close on March 7, 2024, subject to standard closing conditions, with an option for initial purchasers to acquire additional notes.
Read more →IRTC▼ -9.5%on this newsshared move
IRHYTHM ANNOUNCES PROPOSED OFFERING OF $450.0 MILLION OF CONVERTIBLE SENIOR NOTES SAN FRANCISCO, MARCH 4, 2024 (GLOBE NEWSWIRE) iRhythm Technologies, Inc. ( iRhythm ) (NASDAQ:IRTC), a leading digital health care company
iRhythm Technologies, Inc. announced a proposed offering of $450 million in convertible senior notes due in 2029. The offering is aimed at qualified institutional buyers and is subject to market conditions. Proceeds from the offering will be used for various corporate purposes, including the repayment of existing debt and potential share repurchases. An estimated $80.1 million is expected to repay outstanding indebtedness, while the remaining funds will be allocated toward general corporate activities, including research and development.
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (In thousands, except per share data) (Unaudited) Three Months Ended December 31, Year Ended
iRhythm Technologies reported its Q4 and full-year 2023 financial results, showcasing a revenue increase of 17.7% in Q4, driven by heightened demand for its Zio services. However, the company experienced an increased net loss of $38.7 million during the quarter, up from $20.2 million the previous year, and a decline in gross margins. Looking ahead, iRhythm forecasts revenue growth for 2024 between $575 million and $585 million, despite the operational challenges reflected in higher expenses and losses.
Read more →IRTC▲ +7.3%on this news
iRhythm Technologies Shares Preliminary Fourth Quarter 2023 Highlights and Business Update at the 42nd Annual J.P. Morgan Healthcare Conference SAN FRANCISCO, JANUARY 8, 2024 (GLOBE NEWSWIRE) - iRhythm Technologies, Inc.
iRhythm Technologies announced preliminary fourth-quarter highlights and a business update at the 42nd Annual J.P. Morgan Healthcare Conference, showcasing their focus on organizational efficiency and financial sustainability. The company closed a five-year non-dilutive debt facility worth up to $150 million, which will be used to repay outstanding debt and support general corporate purposes. Executives expressed excitement about future growth driven by their innovative cardiac monitoring solutions. They also highlighted their commitment to enhancing patient care while navigating various risks associated with market uncertainties.
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (unaudited) (in thousands, except per share data) Three Months Ended September 30, Nine Months Ended
iRhythm Technologies reported a strong financial performance for Q3 2023, with revenues reaching $124.6 million, reflecting a 20% increase from the previous year. The company also raised its full-year revenue guidance to between $487.5 million and $490 million, citing robust growth in Zio services. However, the gross margin declined and net losses widened due to increased operating expenses. The launch of their next-generation Zio monitor and opening of a business services center in the Philippines are key operational highlights.
Read more →IRTCReconciliation of GAAP to Non GAAP Financial Information Three Months Ended December 31, Year Ended
iRhythm Technologies, Inc. reported strong financial results for Q4 and full year 2022, showcasing a significant revenue growth of 37.7% in Q4. Despite a net loss of $20.2 million for the quarter and a total annual loss of $116.2 million, the company achieved a positive adjusted EBITDA of $1.1 million in Q4. The report highlighted improvements in gross margins, driven by higher selling prices and operational efficiencies, while cash reserves increased to $213.1 million. Looking ahead, iRhythm projects revenue growth of 16% to 18% for 2023, indicating confidence in its ongoing strategy and market position.
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (unaudited) (in thousands, except per share data) Three Months Ended September 30, Nine Months Ended September 30, Adjusted EBITDA recon
iRhythm Technologies Announces Third Quarter 2022 Financial Results SAN FRANCISCO, November 1, 2022 - iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today reported f
Read more →IRTCIRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (Unaudited) (In thousands) Three Months Ended June 30, Six Months Ended June 30, Adjusted EBITDA reconciliation 2022 2021 2022 2021 Net
iRhythm Technologies Announces Second Quarter 2022 Financial Results SAN FRANCISCO, August 4, 2022 - iRhythm Technologies, Inc. (NASDAQ IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today reported financial results for the thre
Read more →About iRhythm Holdings, Inc.
Headquarters699 8TH STREET, San Francisco, CA, 94103
BIOPHARMAWATCH ELITE PLUS
Trade the next IRTC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime